投稿咨询
Epigenomics provides the forum to address the rapidly progressing research developments in this ever-expanding field; to report on the major challenges ahead and critical advances that are propelling the science forward. The journal delivers this information in concise, at-a-glance article formats – invaluable to a time constrained community.
Substantial developments in our current knowledge and understanding of genomics and epigenetics are constantly being made, yet this field is still in its infancy. Epigenomics provides a critical overview of the latest and most significant advances as they unfold and explores their potential application in the clinical setting.
《Epigenomics》是一本由Future Medicine Ltd.出版商出版的专业医学期刊，该刊创刊于2009年，刊期16 issues/year，该刊已被国际权威数据库SCIE收录。在中科院最新升级版分区表中，该刊分区信息为大类学科：医学 2区，小类学科：遗传学 2区；在JCR（Journal Citation Reports）分区等级为Q2。该刊发文范围涵盖遗传学等领域，旨在及时、准确、全面地报道国内外遗传学工作者在该领域取得的最新研究成果、工作进展及学术动态、技术革新等，促进学术交流，鼓励学术创新。2021年影响因子为4.357，平均审稿速度>12周，或约稿。
| 大类学科 | 分区 | 小类学科 | 分区 | Top期刊 | 综述期刊 |
| 医学 | 3区 | GENETICS & HEREDITY 遗传学 | 4区 | 否 | 否 |
| JCR分区等级 | JCR所属学科 | 分区 | 影响因子 |
| Q2 | GENETICS & HEREDITY | Q2 | 4.357 |
| 影响因子 | h-index | Gold OA文章占比 | 研究类文章占比 | OA开放访问 | 平均审稿速度 |
| 4.357 | 44 | 17.29% | 82.73% | 未开放 | >12周，或约稿 |
课题、SCI/EI/SSCI怎么写？